Jim Cramer Shares Thoughts on Novavax and Other Stocks

During a recent segment on CNBC's "Mad Money Lightning Round," host Jim Cramer expressed that he is "not a fan" of Novavax, Inc. (NVAX), a company known for its COVID-19 vaccines. Cramer made these remarks following Novavax's announcement on December 4 that it would sell its manufacturing facility located in Bohumil, Czech Republic, to Novo Nordisk A/S (NVO) for a substantial $200 million.

In addition to this sale, Cramer noted that the Food and Drug Administration has recently granted Emergency Use Authorization for an updated version of Novavax's COVID-19 vaccine. This vaccine is currently listed among the recommendations from the U.S. Centers for Disease Control and Prevention (CDC). It is particularly significant as it is the only protein-based vaccine available in the United States for individuals aged 12 and older, aimed at preventing COVID-19.

Later in the segment, when discussing Alliance Entertainment (LNT), Cramer stated that Live Nation (LYV) is a more attractive investment option. He highlighted how the entertainment giant has performed better in the current market.

On October 31, Alliant Energy (LNT) reported quarterly results that exceeded expectations.

When asked about Nebius Group N.V. (NBIS), Cramer was critical, stating that if he were looking for opportunities in artificial intelligence, he would prefer NVIDIA (NVDA) as it cools down. On December 2, Nebius Group announced it had secured a $700 million private placement financing deal with institutional investors.

Cramer also commented on Innodata Inc. (INOD), describing it as a "very expensive" stock. He advised that if investors wanted to take some profits, they should do so, as there would be opportunities to reinvest later. On November 7, Innodata had revealed financial results for the third quarter that surpassed expectations.

Addressing Smith & Wesson Brands (SWBI), Cramer remarked that while it’s not particularly appealing to him, it may not be a bad entry point for investors. He shared that on December 6, both Lake Street and Craig-Hallum had downgraded Smith & Wesson from "Buy" to "Hold," cutting their price targets from $18 to $13.

Cramer highlighted his disappointment with United Parcel Service, Inc. (UPS), pointing out that the stock has declined significantly and is not a great buy heading into the holiday season. Additionally, the Securities and Exchange Commission (SEC) announced on November 22 that UPS settled charges regarding a misrepresentation of earnings related to its valuation practices.

When discussing BigBear.ai Holdings, Inc. (BBAI), Cramer expressed his hesitation in recommending it. He stressed that he prefers to invest in AI stocks that are on solid footing financially. On November 5, BigBear.ai revealed that its third-quarter revenue results were lower than anticipated.

Price Movements:

• Shares of Alliance Entertainment fell by 0.3% to close at $60.91.
• Nebius Group's stock plummeted by 13.1%, closing at $31.96.
• Novavax saw a 1.5% rise, ending the day at $9.07.
• Innodata's shares dropped 2.1%, closing at $43.63.
• Smith & Wesson saw a gain of 4.2%, finishing at $11.32.
• UPS shares increased by 2.3%, closing at $128.53 during the session.
• BigBear.ai's shares jumped by 8.3%, closing at $3.66.

Disclaimer: Stock investing has risks and past performance is not indicative of future results.

Cramer, Stocks, Novavax